证券代码：688136 证券简称：科兴制药 公告编号：2025-006 科兴生物制药股份有限公司 关于以集中竞价交易方式回购公司股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份价格：不超过人民币 29.77 元/股（含）， 该价格不高于公司董事会通 过回购决议前 30 个交易日公司股票交易均价的 150%。 ● 相关股东是否存在减持计划：截至回购预案披露日，公司董事、监事、高级管 理人员、控股股东、实际控制人、回购股份提议人、持股 5%以上的股东在未来 3 个月、未来 6 个月内暂不存在减持公司股份的计划。若未来拟实施股份减持计划， 将严格按照中国证监会、上海证券交易所有关法律、法规及规范性文件的相关规 定及时告知公司并履行相关信息披露义务。 ● 相关风险提示： 1、本次回购股份存在回购期限内公司股票价格持续超出回购价格上限，导致 回购方案无法实施或只能部分实施的风险； 2、若公司在实施回购股份期间，受外部环境变化、公司临时经营需要、投资 等因素影响，致使本次回购股份所需资金未能 ...

证券代码：688136 证券简称：科兴制药 公告编号：2025-004 科兴生物制药股份有限公司 第二届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 科兴生物制药股份有限公司 董事会 经各位董事认真审议，会议形成了如下决议： （一）审议通过《关于以集中竞价交易方式回购公司股份方案的议案》 经审议，董事会同意公司使用自有资金和回购专项贷款通过集中竞价交易方 式回购公司已发行的部分人民币普通股（A 股）股票。本次回购股份在未来适宜 时机用于股权激励或员工持股计划，回购价格不超过 29.77 元/股（含），回购资 金总额不低于人民币 3,000 万元（含），不超过人民币 6,000 万元（含），具体回 购资金总额以实际使用的资金总额为准。同时，为顺利、高效完成公司本次回购 股份事项的相关工作，董事会授权公司管理层在法律法规、《公司章程》允许的 范围内办理本次回购股份的相关事宜。根据相关法律法规及《公司章程》的有关 规定，本次回购股份方案无需提交公司股东大会审议。 具体内容详 ...

Financial Performance - The company achieved total operating revenue of 140,675.89 million yuan, representing a year-on-year increase of 11.73%[3]. - The net profit attributable to the parent company was 3,153.15 million yuan, a significant turnaround from a loss of 19,029.03 million yuan in the previous year[3]. - The basic earnings per share increased to 0.16 yuan from a loss of 0.96 yuan in the previous year[3]. - The weighted average return on net assets improved to 1.94%, an increase of 13.05 percentage points compared to the previous year[3]. - Total assets at the end of the reporting period were 316,190.03 million yuan, up 4.32% from the beginning of the period[3]. Cost Management - The company effectively controlled operating costs, leading to a decrease in sales, research and development, and production costs[7]. Revenue Sources - The significant growth in overseas revenue was driven by sales of paclitaxel albumin in the EU region[7]. Non-Recurring Gains and Losses - Non-recurring gains and losses were positively impacted by government subsidies and changes in the fair value of private equity funds held by the company[8]. - The company is currently awaiting the audit report and final valuation of its private equity fund, which may affect its non-recurring gains and losses for 2024[9]. Financial Reporting - The financial data presented is preliminary and subject to final confirmation in the annual report[2].

Group 1 - The core point of the article is the strategic cooperation between Sinovac Biotech and Zhejiang Jiuying Technology, a wholly-owned subsidiary of Baicheng Pharmaceutical, focusing on innovative drug development and overseas commercialization [1] Group 2 - The signing ceremony for the strategic cooperation took place on February 24 in Shenzhen [1] - The collaboration presents opportunities for both companies to establish deep and diversified strategic partnerships in multiple fields [1]

证券代码：688136 证券简称：科兴制药 公告编号：2025-002 科兴生物制药股份有限公司 自愿披露关于人干扰素α1b 吸入溶液 获得美国 FDA 新药临床试验许可的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，科兴生物制药股份有限公司（以下简称"公司"）全资子公司深圳科 兴药业有限公司（以下简称"深圳科兴"）收到美国食品药品监督管理局（以下 简称"FDA"）的通知，深圳科兴自主研发的人干扰素α1b吸入溶液药品临床试 验申请已获得FDA批准，可在美国开展临床试验，适应症为小儿呼吸道合胞病毒 性下呼吸道感染（肺炎、毛细支气管炎）。现将相关情况公告如下： 一、许可基本情况 药品名称：人干扰素α1b吸入溶液 公司人干扰素α1b吸入溶液适应症为小儿呼吸道合胞病毒性下呼吸道感染 （肺炎、毛细支气管炎）。呼吸道合胞病毒（RSV）是引起婴幼儿急性呼吸道感 染最常见的病毒病原，5岁以下儿童为易感人群，特别是婴幼儿或有基础疾病的 患儿，感染后容易发展为重症肺炎，WHO关于儿童急性呼吸道感染的病因学研究 1 表明，RSV感 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company is expected to turn profitable in 2024, with a projected revenue growth of over 10% year-on-year and a net profit of approximately 30 million yuan [4] - The overseas revenue is anticipated to grow by over 60% year-on-year, driven by the approval of albumin paclitaxel in the EU, which has opened and deepened the EU market [4][5] - The company is focusing on cost reduction and efficiency improvement, with decreases in sales, R&D, and production costs compared to 2024 [4] - Long-term growth is expected as the company continues to introduce products and expand its overseas business [4] Financial Summary - Revenue is projected to increase from 1,316 million yuan in 2022 to 2,412 million yuan in 2026, reflecting a compound annual growth rate (CAGR) of approximately 31.3% [6] - The net profit is expected to recover from a loss of 90 million yuan in 2022 to a profit of 228 million yuan in 2026 [6] - The earnings per share (EPS) is forecasted to rise from -0.45 yuan in 2022 to 1.14 yuan in 2026 [6] - The price-to-earnings (P/E) ratio is projected to decrease from -37.8 in 2022 to 15.0 in 2026, indicating improved valuation as profitability returns [6]

Financial Performance - The company expects to achieve a net profit of approximately 30 million yuan for 2024, a turnaround from a net loss of 190.29 million yuan in the same period last year[3]. - The net profit attributable to the parent company, excluding non-recurring gains and losses, is projected to be around 33 million yuan, compared to a loss of 201.21 million yuan last year[3]. - Revenue is expected to grow by over 10% compared to the previous year, with overseas sales increasing by over 60% due to the commercialization strategy in the EU market[5][6]. Market Strategy - The company has successfully launched paclitaxel in the EU, significantly enhancing its market presence[5]. - Domestic market revenue is showing steady growth, supported by refined management and targeted marketing strategies[6]. Cost Management - Sales, research and development expenses, and production costs have all decreased compared to the previous year, contributing to improved profitability[6]. Non-Recurring Items - The company received government subsidies and experienced changes in the fair value of its private equity fund holdings, impacting non-recurring gains and losses[6]. Financial Reporting - The financial data provided is preliminary and has not yet been audited by external accountants, which may affect the final reported figures[7][8]. - The company emphasizes the importance of monitoring investment risks related to the preliminary financial data[8].

Group 1 - The core viewpoint of the news is that Kexing Pharmaceutical is making significant progress in overseas commercialization, with multiple product approvals and collaborations announced in December 2025, indicating a strong push into international markets [1] - Kexing Pharmaceutical has entered into a partnership with Jiangxi Kairui Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, to introduce Enzalutamide Soft Capsules in 11 countries and regions, including Brazil, Argentina, and Colombia [1][2] - The collaboration on Enzalutamide Soft Capsules marks the second product partnership between Kexing and Qingfeng, following the earlier agreement on Olaparib tablets in April 2024 [1] Group 2 - Enzalutamide is a drug targeting advanced prostate cancer, particularly for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) and symptomatic metastatic castration-resistant prostate cancer (CRPC) patients [2] - In 2022, there were 1.467 million new cases of prostate cancer globally, making it the second most common cancer among men, with incidence rates increasing with age [2] - The global incidence of prostate cancer increased by 42% from 2007 to 2017, with Brazil reporting 62 new cases per 100,000 men [2] Group 3 - Enzalutamide is recognized as a new generation treatment for prostate cancer, with significant efficacy and safety, and it is the most comprehensive androgen receptor inhibitor for prostate cancer indications [3] - The global sales of Enzalutamide exceeded $5 billion in 2023, indicating a substantial market demand [3] - The partnership between Kexing and Qingfeng aims to leverage their strengths for mutual growth and to benefit more patients, enhancing Kexing's product line in oncology [3]

证券代码：688136 证券简称：科兴制药 公告编号：2024-076 科兴生物制药股份有限公司 关于使用部分闲置募集资金和自有资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 科兴生物制药股份有限公司（以下简称"公司"）于 2024 年 12 月 26 日召开 第二届董事会第二十次会议、第二届监事会第十八次会议，审议通过了《关于使 用部分闲置募集资金和自有资金进行现金管理的议案》，同意公司在不影响公司 募集资金投资项目（以下简称"募投项目"）正常实施并保证募集资金安全的前 提下，使用最高余额不超过 2 亿元（含 2 亿）的部分闲置募集资金及最高余额不 超过 3 亿元（含 3 亿元）的自有资金进行现金管理。现将有关事项公告如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意科兴生物制药股份有限公司首 次公开发行股票注册的批复》（证监许可[2020]2655 号）同意，公司首次公开发 行人民币普通股 4,967.5300 万股，每股面值人民币 1.00 元，每股发行价为人民 币 22. ...

二○二四年十二月 | 第一章 | 总则 2 | | --- | --- | | 第二章 | 经营宗旨和范围 3 | | 第三章 | 股份 3 | | 第四章 | 股东和股东大会 7 | | 第五章 | 董事会 27 | | 第六章 | 总经理及其他高级管理人员 36 | | 第七章 | 监事会 38 | | 第八章 | 财务会计制度、利润分配和审计 41 | | 第九章 | 通知和公告 47 | | 第十章 | 合并、分立、增资、减资、解散和清算 48 | | 第十一章 | 修改章程 51 | | 第十二章 | 附则 51 | 科兴生物制药股份有限公司章程 第一章 总则 第一条 为维护科兴生物制药股份有限公司（以下简称"公司"）、公司股 东和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司章程指引》（以下简称"《章程指引》"）、《上海证券交易所科创板股票 上市规则》（以下简称"《科创板上市规则》"）和其他有关规定，制订本章程。 科兴生物制药股份有限公司 章程 第二条 公司系依照《公司法》和其他法律 ...